|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNM1 |
Gene summary for DNM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNM1 | Gene ID | 1759 |
| Gene name | dynamin 1 | |
| Gene Alias | DEE31 | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0002029 | UniProtAcc | Q05193 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1759 | DNM1 | HCC1_Meng | Human | Liver | HCC | 1.94e-03 | -3.73e-03 | 0.0246 |
| 1759 | DNM1 | HCC1 | Human | Liver | HCC | 2.52e-02 | 1.43e+00 | 0.5336 |
| 1759 | DNM1 | S014 | Human | Liver | HCC | 5.82e-33 | 1.01e+00 | 0.2254 |
| 1759 | DNM1 | S015 | Human | Liver | HCC | 5.65e-28 | 8.58e-01 | 0.2375 |
| 1759 | DNM1 | S016 | Human | Liver | HCC | 2.09e-37 | 1.01e+00 | 0.2243 |
| 1759 | DNM1 | S027 | Human | Liver | HCC | 4.78e-09 | 5.42e-01 | 0.2446 |
| 1759 | DNM1 | S028 | Human | Liver | HCC | 3.43e-18 | 5.17e-01 | 0.2503 |
| 1759 | DNM1 | S029 | Human | Liver | HCC | 7.71e-11 | 4.00e-01 | 0.2581 |
| 1759 | DNM1 | ATC09 | Human | Thyroid | ATC | 1.12e-05 | 2.16e-01 | 0.2871 |
| 1759 | DNM1 | ATC12 | Human | Thyroid | ATC | 5.13e-22 | 4.26e-01 | 0.34 |
| 1759 | DNM1 | ATC13 | Human | Thyroid | ATC | 1.51e-53 | 1.06e+00 | 0.34 |
| 1759 | DNM1 | ATC1 | Human | Thyroid | ATC | 8.73e-06 | 2.51e-01 | 0.2878 |
| 1759 | DNM1 | ATC4 | Human | Thyroid | ATC | 3.45e-27 | 5.05e-01 | 0.34 |
| 1759 | DNM1 | ATC5 | Human | Thyroid | ATC | 1.60e-62 | 1.12e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010769110 | Skin | SCCIS | regulation of cell morphogenesis involved in differentiation | 13/919 | 96/18723 | 8.15e-04 | 1.10e-02 | 13 |
| GO:0051438110 | Skin | SCCIS | regulation of ubiquitin-protein transferase activity | 9/919 | 53/18723 | 1.01e-03 | 1.25e-02 | 9 |
| GO:005076714 | Skin | SCCIS | regulation of neurogenesis | 32/919 | 364/18723 | 1.08e-03 | 1.32e-02 | 32 |
| GO:005196013 | Skin | SCCIS | regulation of nervous system development | 37/919 | 443/18723 | 1.18e-03 | 1.40e-02 | 37 |
| GO:0001666112 | Skin | SCCIS | response to hypoxia | 28/919 | 307/18723 | 1.25e-03 | 1.46e-02 | 28 |
| GO:190262412 | Skin | SCCIS | positive regulation of neutrophil migration | 6/919 | 28/18723 | 2.05e-03 | 2.11e-02 | 6 |
| GO:0031669111 | Skin | SCCIS | cellular response to nutrient levels | 21/919 | 215/18723 | 2.13e-03 | 2.17e-02 | 21 |
| GO:0008637111 | Skin | SCCIS | apoptotic mitochondrial changes | 13/919 | 107/18723 | 2.23e-03 | 2.24e-02 | 13 |
| GO:0036293112 | Skin | SCCIS | response to decreased oxygen levels | 28/919 | 322/18723 | 2.51e-03 | 2.43e-02 | 28 |
| GO:003134618 | Skin | SCCIS | positive regulation of cell projection organization | 30/919 | 353/18723 | 2.54e-03 | 2.44e-02 | 30 |
| GO:009706114 | Skin | SCCIS | dendritic spine organization | 11/919 | 84/18723 | 2.63e-03 | 2.48e-02 | 11 |
| GO:006099814 | Skin | SCCIS | regulation of dendritic spine development | 9/919 | 61/18723 | 2.77e-03 | 2.60e-02 | 9 |
| GO:0070585111 | Skin | SCCIS | protein localization to mitochondrion | 14/919 | 125/18723 | 3.31e-03 | 2.97e-02 | 14 |
| GO:0045807110 | Skin | SCCIS | positive regulation of endocytosis | 12/919 | 100/18723 | 3.59e-03 | 3.17e-02 | 12 |
| GO:0070482112 | Skin | SCCIS | response to oxygen levels | 29/919 | 347/18723 | 3.77e-03 | 3.27e-02 | 29 |
| GO:009917313 | Skin | SCCIS | postsynapse organization | 17/919 | 168/18723 | 3.77e-03 | 3.27e-02 | 17 |
| GO:0030100110 | Skin | SCCIS | regulation of endocytosis | 20/919 | 211/18723 | 3.79e-03 | 3.28e-02 | 20 |
| GO:009002312 | Skin | SCCIS | positive regulation of neutrophil chemotaxis | 5/919 | 24/18723 | 5.49e-03 | 4.34e-02 | 5 |
| GO:009719329 | Skin | cSCC | intrinsic apoptotic signaling pathway | 150/4864 | 288/18723 | 1.76e-21 | 3.34e-19 | 150 |
| GO:200123329 | Skin | cSCC | regulation of apoptotic signaling pathway | 173/4864 | 356/18723 | 2.25e-20 | 3.44e-18 | 173 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0510022 | Liver | HCC | Bacterial invasion of epithelial cells | 51/4020 | 77/8465 | 6.67e-04 | 2.72e-03 | 1.52e-03 | 51 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0510032 | Liver | HCC | Bacterial invasion of epithelial cells | 51/4020 | 77/8465 | 6.67e-04 | 2.72e-03 | 1.52e-03 | 51 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNM1 | SNV | Missense_Mutation | novel | c.370G>T | p.Val124Phe | p.V124F | Q05193 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| DNM1 | SNV | Missense_Mutation | rs755327329 | c.1319N>A | p.Arg440Lys | p.R440K | Q05193 | protein_coding | tolerated(0.19) | benign(0.09) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DNM1 | SNV | Missense_Mutation | novel | c.536C>T | p.Ser179Phe | p.S179F | Q05193 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| DNM1 | SNV | Missense_Mutation | c.767G>T | p.Arg256Leu | p.R256L | Q05193 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| DNM1 | SNV | Missense_Mutation | c.1978G>C | p.Glu660Gln | p.E660Q | Q05193 | protein_coding | deleterious(0.02) | probably_damaging(0.988) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNM1 | SNV | Missense_Mutation | rs773857861 | c.1394N>A | p.Arg465Gln | p.R465Q | Q05193 | protein_coding | deleterious(0.03) | possibly_damaging(0.788) | TCGA-C8-A1HG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DNM1 | SNV | Missense_Mutation | novel | c.623N>G | p.Asp208Gly | p.D208G | Q05193 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| DNM1 | SNV | Missense_Mutation | c.1564N>T | p.Arg522Cys | p.R522C | Q05193 | protein_coding | deleterious(0.05) | probably_damaging(0.954) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| DNM1 | SNV | Missense_Mutation | c.2001N>A | p.Asp667Glu | p.D667E | Q05193 | protein_coding | tolerated(0.1) | probably_damaging(0.989) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD | |
| DNM1 | SNV | Missense_Mutation | novel | c.634G>A | p.Glu212Lys | p.E212K | Q05193 | protein_coding | deleterious(0.04) | probably_damaging(0.97) | TCGA-E9-A2JT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |